Alvotech and dr. reddy's enter into collaboration for commercialization of avt03 (denosumab), a biosimilar candidate to prolia® & xgeva® in the u.s., europe and uk

Hyderabad, india & reykjavik, iceland — alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“alvotech”), and dr. reddy's laboratories sa, wholly-owned subsidiary of dr. reddy's laboratories ltd., (bse: 500124 | nse: drreddy | nyse: rdy | nseifsc: drreddy, along with its subsidiaries hereafter referred to as “dr. reddy's”), today announced that the companies have entered into a license and supply agreement for the commercialization of avt03, alvotech's biosimilar candidate to prolia® and xgeva® (denosumab). the collaboration combines dr. reddy's global commercial presence with alvotech's proven capabilities in developing biosimilars for markets worldwide.
ALVO Ratings Summary
ALVO Quant Ranking